Targeted Therapies in Multiple Myeloma Video Perspectives
Ajai Chari, MD
Chari reports research support from/being principal investigator for Janssen; and consulting/serving on scientific advisory board for AbbVie, Adaptive, Amgen, Antengene, BMS, Forus, Genentech/Roche, GSK, Janssen, Karyopharm, Millenium/Takeda and Sanofi/Genzyme.
VIDEO: Exploring targeted therapy in multiple myeloma
Transcript
Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
We can start with the naked antibodies, which target CD38 and SLAMF-7. So we have daratumumab and isatuximab targeting CD38 and elotuzumab targeting SLAM-7. But then I think more exciting for the newer targets. So B-cell maturation antigen, known as BCMA, GPRC5D, and we have approved agents for these, and then also FCRH5. And we have an agent under investigation but not yet approved. And the general principle is we're looking for targets that are over expressed in myeloma but not on other tissues. And these are obviously all targets for immunotherapeutic approaches, whether it's naked antibody, antibody drug conjugate, bispecific, or CAR T, all of them are trying to harness the specificity of the target on myeloma but not the other tissue to try to achieve that really optimal efficacy/safety balance.
